{"doi":"10.1002/ejhf.2990","title":"Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial","abstract":"AIMS: Empagliflozin has been shown to reduce the risk of adverse cardiovascular outcomes in patients with type 2 diabetes and in those with heart failure. The impact of empagliflozin in post-acute myocardial infarction (AMI) patients is unknown. METHODS AND RESULTS: The Study to Test the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction (EMPACT-MI) trial screened 6610 participants with AMI and randomized 6522 to empagliflozin or placebo in addition to standard of care. The median (interquartile) age was 64 (56-71) years and 75.1% of patients were male. Major comorbidities included hypertension (69.1%), type 2 diabetes (31.7%), prior myocardial infarction (13.0%), and atrial fibrillation (10.9%). The majority (74.3%) of patients presented with an ST-elevation myocardial infarction. Overall, 56.9% of patients had acute signs or symptoms of congestion requiring treatment and 78.3% had left ventricular systolic dysfunction with ejection fraction <45%. Clinical characteristics, including baseline demographics, rates of revascularization, and cardiovascular medications at discharge were largely comparable to recent trials of the post-AMI population. CONCLUSION: The EMPACT-MI trial will establish the benefit and risks of empagliflozin treatment in patients with AMI.","journal":"European Journal of Heart Failure","year":2023,"id":334769,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":21,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7819,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":266923,"name":"Jacob A. Udell","orcid":"0000-0001-7402-9584","position":1,"is_corresponding":false},{"id":302876,"name":"W. Schuyler Jones","orcid":"0000-0002-7288-9596","position":2,"is_corresponding":false},{"id":2614,"name":"Stefan D. Anker","orcid":"0000-0003-3331-7314","position":3,"is_corresponding":false},{"id":3774,"name":"Deepak L. Bhatt","orcid":"0000-0002-1278-6245","position":4,"is_corresponding":false},{"id":57272,"name":"Mark C. Petrie","orcid":"0000-0002-6333-9496","position":5,"is_corresponding":false},{"id":1064182,"name":"Knut Robert Andersen","orcid":null,"position":6,"is_corresponding":false},{"id":1063671,"name":"Mikhail Sumin","orcid":"0000-0002-3827-5793","position":7,"is_corresponding":false},{"id":1063672,"name":"Isabella Zwiener","orcid":"0000-0003-1326-9212","position":8,"is_corresponding":false},{"id":51666,"name":"Adrian F. Hernandez","orcid":"0000-0003-3387-9616","position":9,"is_corresponding":false},{"id":49613,"name":"Javed Butler","orcid":"0000-0001-7683-4720","position":10,"is_corresponding":false},{"id":850371,"name":"Josephine Harrington","orcid":null,"position":0,"is_corresponding":true}],"reference_count":30,"raw_metadata":null,"created_at":"2026-07-19T01:09:53.742667Z","pmid":"37622416","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}